Immunogenicity Testing
Immunogenicity Testing - Related Videos
05:42
Using a Sandwich ELISA to Determine the Immunogenic Glycoprotein Content in a Vaccine
0 Views •
2025
This video showcases an indirect enzyme-linked immunosorbent assay or ELISA sandwich immunocapture assay designed to assess immunogenic glycoprotein levels in vaccines. The assay plate, containing glycoprotein-specific antibodies, is incubated with serially diluted vaccine samples, including reference and test vaccines, followed by immunoassay to quantify glycoprotein content in the test vaccine.
10:52
Preparation of Mouse Pituitary Immunogen for the Induction of Experimental Autoimmune Hypophysitis
0 Views •
Cited by 10 •
2010
Autoimmune hypophysitis can be reproduced in mice by injecting an extract of mouse pituitary proteins.
12:54
Determination of Vaccine Immunogenicity Using Bovine Monocyte-Derived Dendritic Cells
0 Views •
Cited by 1 •
2023
The methodology describes the generation of bovine monocyte-derived dendritic cells (MoDCs) and their application for the in vitro evaluation of antigenic candidates during the development of potential veterinary vaccines in cattle.
12:08
Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells
0 Views •
Cited by 10 •
2019
The transimmunization (TI) device or plate and related protocols have been developed to replicate the key features of extracorporeal photochemotherapy (ECP), in an experimental setting, allowing for production of physiologically activated, tunable dendritic cells (DCs) for cancer immunotherapy.
FAQs
Immunogenicity testing examines more than whether a response occurs: researchers consider its strength, specificity, and persistence. Anti-drug antibodies and neutralizing antibodies provide antibody-focused measurements, while cytokine assays and immune-cell activation measurements add cellular perspectives. Considering these readouts together helps characterize how an engineered biologic, material, or device interacts with the immune system.
These antibody measurements represent distinct assay targets, so using both can provide a more complete characterization than relying on one readout. The comparison helps researchers assess the specificity and persistence of antibody-related responses and determine whether an engineered therapeutic or biologic warrants further evaluation alongside cytokine or immune-cell measurements.
Antibody assays focus on anti-drug or neutralizing antibodies, whereas cytokine measurements and immune-cell activation assays capture other dimensions of the response. This broader panel is useful when researchers need to characterize potential inflammatory reactions and assess biocompatibility, particularly for engineered materials or devices whose immune effects may not be represented by antibody measurements alone.
Researchers commonly begin with in vitro assays to examine responses to the therapeutic, biomaterial, or device. When appropriate, they extend the evaluation to animal or clinical studies, allowing response characterization after exposure in additional settings. This staged approach supports assessment of strength, specificity, and persistence before a technology advances toward clinical use.
Results can guide changes to the engineered product rather than serving only as a safety record. In bioengineering, findings may inform protein design, surface modification, and formulation, while also contributing to biocompatibility assessment. These uses connect measured immune responses with product development and help teams address concerns before clinical advancement.
It is especially relevant when a therapeutic, biomaterial, or medical device is being evaluated for product safety and future clinical use. The findings can help identify risks associated with reduced efficacy, inflammatory reactions, or other unwanted responses before advancement. This makes the testing informative for both biologic development and the assessment of engineered materials and devices.